尿液CCL14与第一代尿液生物标志物预测急性肾损伤肾功能恢复的前瞻性探索性研究
该前瞻性探索性研究纳入ICU入住后发生AKI的患者164例,在AKI诊断当日检测尿液TIMP-2、IGFBP7、CCL14和NGAL,主要终点为7天内AKI未恢复。64例(39.0%)未恢复;CCL14预测未恢复的AUC为0.71(95%CI 0.63-0.77,p<0.001),[TIMP-2]×[IGFBP7]的AUC为0.78(95%CI 0.71-0.84,p<0.001),NGAL无预测价值(AUC 0.53,95%CI 0.45-0.60,p=0.562)。由非肾脏SOFA评分和AKI分期构成的两参数模型AUC为0.77(95%CI 0.77-0.83,p=0.004),[TIMP-2]×[IGFBP7]与临床因素联合后AUC显著提高至0.82(95%CI 0.74-0.87,p=0.049)。作者认为CCL14与[TIMP-2]×[IGFBP7]对AKI未恢复具有尚可的预测能力,联合临床模型可增强预测效能。
要点
- 在164例ICU AKI患者中,64例(39.0%)在7天内未恢复肾功能。
- 尿液[TIMP-2]×[IGFBP7]预测7天未恢复的AUC为0.78(95%CI 0.71-0.84,p<0.001),优于CCL14的AUC 0.71(95%CI 0.63-0.77,p<0.001)。
- 尿液NGAL对预测AKI未恢复无价值,AUC为0.53(95%CI 0.45-0.60,p=0.562)。
- 非肾脏SOFA评分联合AKI分期的两参数模型AUC为0.77(95%CI 0.77-0.83,p=0.004)。
- [TIMP-2]×[IGFBP7]联合临床因素后AUC显著提高至0.82(95%CI 0.74-0.87,p=0.049)。
适用人群与场景
- ICU入住后发生AKI的患者,在AKI诊断当日检测尿液生物标志物。
研究设计与关键结果
- 前瞻性探索性研究,纳入164例ICU AKI患者,64例(39.0%)在7天内未恢复。
- CCL14预测未恢复的AUC为0.71(95%CI 0.63-0.77,p<0.001)。
- [TIMP-2]×[IGFBP7]预测未恢复的AUC为0.78(95%CI 0.71-0.84,p<0.001)。
- NGAL预测未恢复的AUC为0.53(95%CI 0.45-0.60,p=0.562)。
- 非肾脏SOFA评分和AKI分期两参数模型预测未恢复的AUC为0.77(95%CI 0.77-0.83,p=0.004)。
- [TIMP-2]×[IGFBP7]联合临床因素后AUC显著提高至0.82(95%CI 0.74-0.87,p=0.049)。
证据类型、等级与局限
- 证据类型:前瞻性探索性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为尿液CCL14和[TIMP-2]×[IGFBP7]对AKI未恢复具有尚可的预测能力。
- 作者认为将尿液[TIMP-2]×[IGFBP7]与非肾脏SOFA评分和AKI分期构成的临床模型联合可增强对AKI未恢复的预测效能。
- 作者认为与[TIMP-2]×[IGFBP7]相比,尿液CCL14在预测AKI未恢复方面无显著优势。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute kidney injury (AKI) is a frequent syndrome in the intensive care unit (ICU). AKI patients with kidney function recovery have better short-term and long-term prognoses compared with those with non-recovery. Numerous studies focus on biomarkers to distinguish them. To better understand the predictive performance of urinary biomarkers of renal recovery in patients with AKI, we evaluated C-C motif chemokine ligand 14 (CCL14) and two first-generation biomarkers (cell cycle arrest biomarkers and neutrophil gelatinase-associated lipocalin) in two ICU settings.
METHODS: We performed a prospective study to analyze urinary biomarkers for predicting renal recovery from AKI. Patients who developed AKI after ICU admission were enrolled and urinary biomarkers including tissue inhibitor of metalloproteinase-2 (TIMP-2), insulin-like growth factor-binding protein 7 (IGFBP7), CCL14, and neutrophil gelatinase-associated lipocalin (NGAL) were detected on the day of AKI diagnosis. The primary endpoint was non-recovery from AKI within 7 days. The individual discriminative ability of CCL14, [TIMP-2] × [IGFBP7] and NGAL to predict renal non-recovery were evaluated by the area under receiver operating characteristics curve (AUC).
RESULTS: Of 164 AKI patients, 64 (39.0%) failed to recover from AKI onset. CCL14 showed a fair prediction ability for renal non-recovery with an AUC of 0.71 (95% CI 0.63-0.77, p < 0.001). [TIMP-2] × [IGFBP7] showed the best prediction for renal non-recovery with an AUC of 0.78 (95% CI 0.71-0.84, p < 0.001). However, NGAL had no use in predicting non-recovery with an AUC of 0.53 (95% CI 0.45-0.60, p = 0.562). A two-parameter model (non-renal SOFA score and AKI stage) predicted renal non-recovery with an AUC of 0.77 (95% CI 0.77-0.83, p = 0.004). When [TIMP-2] × [IGFBP7] was combined with the clinical factors, the AUC was significantly improved to 0.82 (95% CI 0.74-0.87, p = 0.049).
CONCLUSIONS: Urinary CCL14 and [TIMP-2] × [IGFBP7] were fair predictors of renal non-recovery from AKI. Combing urinary [TIMP-2] × [IGFBP7] with a clinical model consisting of non-renal SOFA score and AKI stage enhanced the predictive power for renal non-recovery. Urinary CCL14 showed no significant advantage in predicting renal non-recovery compared to [TIMP-2] × [IGFBP7].
参考来源
- Qian BS, Jia HM, Weng YB, et al. Analysis of urinary C-C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study. J Intensive Care. 2023. PMID: 36941674. doi:10.1186/s40560-023-00659-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。